BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhao L, Yang Y, Gao Q. Efficacy and safety of nivolumab plus apatinib in advanced liver carcinosarcoma: a case report. Immunotherapy 2019;11:651-6. [PMID: 31088237 DOI: 10.2217/imt-2018-0214] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Yang Y, Mai W, Chen W, Yang C, Li M, Liu L. Case Report: Low-Dose Apatinib in the Treatment of Intrahepatic Biliary Cystadenoma With Recurrence and Malignant Transformation. Front Oncol 2021;11:676092. [PMID: 34262864 DOI: 10.3389/fonc.2021.676092] [Reference Citation Analysis]
2 Gong A, Li X. The efficacy and safety of Apatinib combined with TACE in the treatment of hepatocellular carcinoma: a meta-analysis. World J Surg Oncol 2022;20:69. [PMID: 35246145 DOI: 10.1186/s12957-021-02451-8] [Reference Citation Analysis]
3 Gao L, Yang X, Yi C, Zhu H. Adverse Events of Concurrent Immune Checkpoint Inhibitors and Antiangiogenic Agents: A Systematic Review. Front Pharmacol 2019;10:1173. [PMID: 31680957 DOI: 10.3389/fphar.2019.01173] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
4 Bin F, Chen Z, Liu P, Liu J, Mao Z. The Clinicopathological and Imaging Characteristics of Primary Hepatic Carcinosarcoma and a Review of the Literature. J Hepatocell Carcinoma 2020;7:169-80. [PMID: 33117751 DOI: 10.2147/JHC.S272768] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Ji W, Xing Y, Ma J, Zhao Z, Xu H, Zheng S, Li W, Li X. Primary Liver Sarcomatoid Carcinoma: A Case Series and Literature Review. J Hepatocell Carcinoma 2021;8:1117-27. [PMID: 34522692 DOI: 10.2147/JHC.S325182] [Reference Citation Analysis]
6 Singh V, Khurana A, Allawadhi P, Banothu AK, Bharani KK, Weiskirchen R. Emerging Role of PD-1/PD-L1 Inhibitors in Chronic Liver Diseases. Front Pharmacol 2021;12:790963. [PMID: 35002724 DOI: 10.3389/fphar.2021.790963] [Reference Citation Analysis]
7 Zhu Z, Wang L, Wang W, Zha Y, Wang X, Han J, Lv W. Sarcomatoid carcinoma in the sinonasal cavity: A retrospective case series from a single institution. Auris Nasus Larynx 2022:S0385-8146(22)00023-2. [PMID: 35183394 DOI: 10.1016/j.anl.2022.01.005] [Reference Citation Analysis]
8 Vasella M, Gousopoulos E, Guidi M, Storti G, Song SY, Grieb G, Pauli C, Lindenblatt N, Giovanoli P, Kim BS. Targeted Therapies and Checkpoint Inhibitors in Sarcoma. QJM 2021:hcab014. [PMID: 33486519 DOI: 10.1093/qjmed/hcab014] [Reference Citation Analysis]